Supranormal Myocardial Creatine and Phosphocreatine Concentrations Lead to Cardiac Hypertrophy and Heart Failure
- 15 November 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 112 (20) , 3131-3139
Abstract
Background— Heart failure is associated with deranged cardiac energy metabolism, including reductions of creatine and phosphocreatine. Interventions that increase myocardial high-energy phosphate stores have been proposed as a strategy for treatment of heart failure. Previously, it has not been possible to increase myocardial creatine and phosphocreatine concentrations to supranormal levels because they are subject to tight regulation by the sarcolemmal creatine transporter (CrT). Methods and Results— We therefore created 2 transgenic mouse lines overexpressing the myocardial creatine transporter (CrT-OE). Compared with wild-type (WT) littermate controls, total creatine (by high-performance liquid chromatography) was increased in CrT-OE hearts (66±6 nmol/mg protein in WT versus 133±52 nmol/mg protein in CrT-OE). Phosphocreatine levels (by 31 P magnetic resonance spectroscopy) were also increased but to a lesser extent. Surprisingly, CrT-OE mice developed left ventricular (LV) dilatation (LV end-diastolic volume: 21.5±4.3 μL in WT versus 33.1±9.6 μL in CrT-OE; P =0.002), substantial LV dysfunction (ejection fraction: 64±9% in WT versus 49±13% in CrT-OE; range, 22% to 70%; P =0.003), and LV hypertrophy (by 3-dimensional echocardiography and magnetic resonance imaging). Myocardial creatine content correlated closely with LV end-diastolic volume ( r =0.51, P =0.02), ejection fraction ( r =−0.74, P =0.0002), LV weight ( r =0.59, P =0.006), LV end-diastolic pressure ( r =0.52, P =0.02), and dP / dt max ( r =−0.69, P =0.0008). Despite increased creatine and phosphocreatine levels, CrT-OE hearts showed energetic impairment, with increased free ADP concentrations and reduced free-energy change levels. Conclusions— Overexpression of the CrT leads to supranormal levels of myocardial creatine and phosphocreatine, but the heart is incapable of keeping the augmented creatine pool adequately phosphorylated, resulting in increased free ADP levels, LV hypertrophy, and dysfunction. Our data demonstrate that a disturbance of the CrT-mediated tight regulation of cardiac energy metabolism has deleterious functional consequences. These findings caution against the uncritical use of creatine as a therapeutic agent in heart disease.Keywords
This publication has 32 references indexed in Scilit:
- Reduced Inotropic Reserve and Increased Susceptibility to Cardiac Ischemia/Reperfusion Injury in Phosphocreatine-Deficient Guanidinoacetate- N -Methyltransferase–Knockout MiceCirculation, 2005
- Mechanisms of creatine depletion in chronically failing rat heartJournal of Molecular and Cellular Cardiology, 2005
- Creatine kinase knockout mice show left ventricular hypertrophy and dilatation, but unaltered remodeling post-myocardial infarctionCardiovascular Research, 2005
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Congestive heart failure: a half century perspectiveEuropean Heart Journal, 2001
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction.Journal of Clinical Investigation, 1995
- Creatine metabolism and the consequences of creatine depletion in muscleMolecular and Cellular Biochemistry, 1994
- Increased levels of messenger ribonucleic acid for apolipoprotein E in the spleen of probucol-treated rabbitsThe American Journal of Cardiology, 1988
- MYOCARDIAL METABOLISM IN CONGESTIVE HEART FAILUREMedicine, 1951